By Gina Shaw
A major multicenter clinical trial will investigate the potential of individualized immune tolerance induction (ITI) therapy to reduce the time it takes to eradicate inhibitors in hemophilia A treatment.
One of the biggest challenges in the management of hemophilia is the development of inhibitors, an immune response to treatment with clotting factor concentrates that reduces the effectiveness of the factors and makes it more difficult to stop bleeding episodes. Approximately one in